Direct Application of Systane Complete to Contact Lenses
Primary Purpose
Dry Eye, Contact Lens Complication
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Systane Complete
Sensitive Eyes Rewetting Drops
Sponsored by
About this trial
This is an interventional treatment trial for Dry Eye focused on measuring Systane Complete, Dry Eye, Contact Lens Discomfort, Artificial Tears, Rewetting Drops
Eligibility Criteria
Inclusion Criteria:
- Daily disposable contact lens wearers
- 20/30 visual acuity or better
- Self-report contact lens discomfort
- Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores ≥ 12
Exclusion Criteria:
- Other contact lens modalities/wear schedules (e.g., two week and monthly replacement CLs, gas permeable CLs)
- Non-compliant daily disposable contact lens wearers
- Systemic health conditions that alter tear film physiology (e.g., primary and secondary Sjögren's syndrome)
- History of ocular surgery within the past 12 months
- History of severe ocular trauma
- History of active ocular infection or inflammation
- Isotretinoin-derivatives use
- Ocular medication use
- Pregnant or breast feeding
Sites / Locations
- University of Alabama at Birmingham
- Lindenhurst Eye Physicians & Surgeons, P.C.
- Southern College of Optometry
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
No Intervention
Arm Label
Systane Complete
Sensitive Eyes Rewetting Drops
No Treatment
Arm Description
Subjects in this group will use Systane Complete before, during, and after contact lens use.
Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
Outcomes
Primary Outcome Measures
Difference in Ocular Surface Damage as Measured by the Brien Holden Vision Institute (BHVI Grading Scale) at Two Weeks
The Corneal Staining Scores are measured by the BHVI grading scale. The grading scales are a quick reference to the key signs associated with contact lens related inflammation and infection. Used as a reference tool in the clinic, they provide a guide for determining how much normal ocular appearance has changed in a patient, and can help inform clinical management decisions. The range of the scores are: 0-4 in five regions (total sum score = 20). A lower score indicates a better outcome.
Secondary Outcome Measures
Identifying Contact Lens (CL) Participants With Dry Eye Disease (DED), as Measured by the Contact Lens Dry Eye Questionnaire-4 Items (CLDEQ-4) Between Two Weeks and Baseline.
The CLDEQ-4 is a contact lens specific symptoms survey; range = 0-18 with 18 being most symptomatic.
Full Information
NCT ID
NCT03848221
First Posted
February 19, 2019
Last Updated
October 3, 2020
Sponsor
University of Alabama at Birmingham
Collaborators
Alcon Research
1. Study Identification
Unique Protocol Identification Number
NCT03848221
Brief Title
Direct Application of Systane Complete to Contact Lenses
Official Title
Direct Application of Systane Complete to Contact Lenses for the Treatment of Contact Lens Discomfort
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
May 28, 2019 (Actual)
Primary Completion Date
October 20, 2019 (Actual)
Study Completion Date
October 20, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
Collaborators
Alcon Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A common first line treatment for patients with dryness symptoms or contact lens discomfort is the application of artificial tears or rewetting drops, respectively. Rewetting drops are specifically formulated for use with contact lenses while artificial tears are indicated for dry eye. Modern rewetting drops and artificial tears have similar formulations with similar preservatives, preservatives that have been shown to be compatible with contact lenses. While rewetting drops and artificial tears are regulated under different U.S. Food & Drug Administration policies, artificial tears are not specifically indicated for direct use with contact lenses. Nevertheless, clinicians commonly prescribe artificial tears to contact lens wearers likely because newer formulations of artificial tear have the potential to outperform available rewetting drops. The safety and efficacy of using artificial tears with contact lenses for the treatment of discomfort is supported by Caffery and Josephson and Ozkan and Papas who found that artificial tears significantly reduces dryness symptoms in contact lens wearers. Thus, the purpose of this study is to test the safety of directly applying a new artificial tear, Systane Complete, to the contact lens wearing eye and its ability to alleviate symptoms while wearing contact lenses during the day.
Detailed Description
Soft contact lenses are the ideal vision correction choice for many patients because soft contact lenses allow patients to have better and less restricted vision, they allow for an increased ability to perform work tasks and play sports, and they provide patients with a better perceived cosmetic appearance compared to spectacle lenses. While millions of people worldwide benefit from contact lenses, many of these patients experience contact lens discomfort, which limits their wear time and in many instances eventually result in discontinuation of contact lens use. In fact, 21% to 64% of contact lens wearers permanently discontinue contact lens use because of ocular discomfort. Contact lens discomfort is currently defined as "a condition characterized by episodic or persistent adverse ocular sensations related to lens wear, either with or without visual disturbance, resulting from reduced compatibility between the contact lens and the ocular environment, which can lead to decreased wearing time and discontinuation of contact lens wear." Although contact lens discomfort may stem from the lens itself, a situation that can be corrected by such means as switching to an alternative material or wear schedule, contact lens discomfort more typically occurs from ocular surface disease.
A common first line treatment for patients with dryness symptoms or contact lens discomfort is the application of artificial tears or rewetting drops, respectively. Rewetting drops are specifically formulated for use with contact lenses while artificial tears are indicated for dry eye. Modern rewetting drops and artificial tears have similar formulations with similar preservatives, preservatives that have been shown to be compatible with contact lens use. While rewetting drops and artificial tears are regulated under different U.S. Food & Drug Administration policies, artificial tears are not specifically indicated for use with contact lenses. Nevertheless, clinicians commonly prescribe artificial tears to contact lens wearers likely because newer formulations of artificial tear have the potential to outperform available rewetting drops (e.g., some artificial tears have lipid supplements that have the potential to restore the external tear lipid layer). The safe and effective use of artificial tears with contact lenses is supported by Caffery and Josephson and Ozkan and Papas who found that artificial tears significantly reduce dryness symptoms in contact lens wearers. However, the community currently lacks a rigorous scientific study aimed at understanding the utility of lipid-containing artificial tear (or rewetting drop) for alleviating contact lens discomfort while patients are wearing their contact lenses. Systane Complete, a new formulation of artificial tears, combines elements from both Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (lipid-containing artificial tear indicated for evaporative dry eye). Thus, the purpose of this study is to test the safety of Systane Complete and its ability to alleviate contact lens discomfort during the day while subjects are wearing their contact lenses. This goal will be accomplished by randomizing subjects to either Systane Complete, a commercially available rewetting drop, or no treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye, Contact Lens Complication
Keywords
Systane Complete, Dry Eye, Contact Lens Discomfort, Artificial Tears, Rewetting Drops
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Investigator Masked, Randomized, Clinical Trial
Masking
Care ProviderInvestigatorOutcomes Assessor
Masking Description
The investigator will be masked to the subject's treatment. The subjects cannot be fully masked because there is a no treatment control group.
Allocation
Randomized
Enrollment
73 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Systane Complete
Arm Type
Experimental
Arm Description
Subjects in this group will use Systane Complete before, during, and after contact lens use.
Arm Title
Sensitive Eyes Rewetting Drops
Arm Type
Active Comparator
Arm Description
Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
Arm Title
No Treatment
Arm Type
No Intervention
Arm Description
Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
Intervention Type
Drug
Intervention Name(s)
Systane Complete
Intervention Description
Systane Complete is an artificial tear.
Intervention Type
Drug
Intervention Name(s)
Sensitive Eyes Rewetting Drops
Intervention Description
Sensitive Eyes Rewetting Drops is a rewetting drop.
Primary Outcome Measure Information:
Title
Difference in Ocular Surface Damage as Measured by the Brien Holden Vision Institute (BHVI Grading Scale) at Two Weeks
Description
The Corneal Staining Scores are measured by the BHVI grading scale. The grading scales are a quick reference to the key signs associated with contact lens related inflammation and infection. Used as a reference tool in the clinic, they provide a guide for determining how much normal ocular appearance has changed in a patient, and can help inform clinical management decisions. The range of the scores are: 0-4 in five regions (total sum score = 20). A lower score indicates a better outcome.
Time Frame
2 Weeks
Secondary Outcome Measure Information:
Title
Identifying Contact Lens (CL) Participants With Dry Eye Disease (DED), as Measured by the Contact Lens Dry Eye Questionnaire-4 Items (CLDEQ-4) Between Two Weeks and Baseline.
Description
The CLDEQ-4 is a contact lens specific symptoms survey; range = 0-18 with 18 being most symptomatic.
Time Frame
2 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Daily disposable contact lens wearers
20/30 visual acuity or better
Self-report contact lens discomfort
Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores ≥ 12
Exclusion Criteria:
Other contact lens modalities/wear schedules (e.g., two week and monthly replacement CLs, gas permeable CLs)
Non-compliant daily disposable contact lens wearers
Systemic health conditions that alter tear film physiology (e.g., primary and secondary Sjögren's syndrome)
History of ocular surgery within the past 12 months
History of severe ocular trauma
History of active ocular infection or inflammation
Isotretinoin-derivatives use
Ocular medication use
Pregnant or breast feeding
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Facility Name
Lindenhurst Eye Physicians & Surgeons, P.C.
City
Babylon
State/Province
New York
ZIP/Postal Code
11702
Country
United States
Facility Name
Southern College of Optometry
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38104
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to share individual subject data.
Learn more about this trial
Direct Application of Systane Complete to Contact Lenses
We'll reach out to this number within 24 hrs